GOOD THERAPEUTICS
Good Therapeutics develops new technology for self-regulating drugs that will provide a therapeutic activity when, where it is needed. It is an early-stage biotechnology company based in Seattle, Washington. They are developing context-dependent protein drugs that sense biomarkers and respond with therapeutic activity. Their goal is to make safer, more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy. Their core technology is an algorithm for designing allosterically-regulated proteins. These proteins change their conformation (shape) when they bind a biomarker or metabolite, and in doing so activate a therapeutic domain. They are currently focused on immuno-oncology applications of the technology.
GOOD THERAPEUTICS
Industry:
Biotechnology Life Science Pharmaceutical
Founded:
2016-01-01
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.goodtherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
(253) 271-4341
Email Addresses:
[email protected]
Total Funding:
30.2 M USD
Similar Organizations
Antengene Corporation
Antengene is a developer of biotechnology and bio-pharmaceuticals intended to provide medicine treatment for tumor.
Arcellx
Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Current Advisors List
Current Employees Featured
Founder
Investors List
RiverVest
RiverVest investment in Series B - Good Therapeutics
Roche Venture Fund
Roche Venture Fund investment in Series B - Good Therapeutics
3ร5 Partners
3ร5 Partners investment in Series B - Good Therapeutics
Digitalis Ventures
Digitalis Ventures investment in Series B - Good Therapeutics
Roche Venture Fund
Roche Venture Fund investment in Series A - Good Therapeutics
Codon Capital
Codon Capital investment in Series A - Good Therapeutics
RiverVest
RiverVest investment in Series A - Good Therapeutics
Digitalis Ventures
Digitalis Ventures investment in Series A - Good Therapeutics
3x5 Partners
3x5 Partners investment in Series A - Good Therapeutics
RiverVest
RiverVest investment in Series A - Good Therapeutics
Official Site Inspections
http://www.goodtherapeutics.com
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Good Therapeutics"
Good Therapeutics Company Profile 2024: Valuation, Investors ...
Good Therapeutics is headquartered in Seattle, WA. What is the size of Good Therapeutics? Good Therapeutics has 26 total employees. What industry is Good Therapeutics in? Good โฆSee details»
Good Therapeutics, Inc. | LinkedIn
Good Therapeutics, Inc. | 3,746 followers on LinkedIn. Systemic delivery, local activity | At Good Therapeutics we are developing protein-based drugs with regulated, context-dependent activity.See details»
Roche acquires Good Therapeutics - 2022-09-07 - Crunchbase
Sep 7, 2022 Acquired Organization: Good Therapeutics Good Therapeutics develops new technology for self-regulating drugs that will provide a therapeutic activity when, where it is โฆSee details»
Good Therapeutics - Funding, Financials, Valuation & Investors
Good Therapeutics develops new technology for self-regulating drugs that will provide a therapeutic activity when, where it is needed. Search Crunchbase. ... How much funding has โฆSee details»
Good Therapeutics Company Profile - Office Locations ... - Craft
Good Therapeutics is a biotechnology company developing protein drugs that sense biomarkers and respond with therapeutic activity. Its core technology is an algorithm for designing proteins โฆSee details»
Good Therapeutics Announces Acquisition of โฆ
Sep 7, 2022 Good Therapeutics Developing PD-1-regulated IL-2 Drugs Based on Innovative Conditionally Active Drug Technology September 07, 2022 07:00 AM Eastern Daylight TimeSee details»
Good Therapeutics lands $8M to develop protein drugs that
Dec 30, 2021 Good Therapeutics is developing an IL-2-based agent that is active when bound to immune T cells that recognize tumors. The therapeutic binds a target on such cells, PD-1, then โฆSee details»
CASE STUDY: GOOD THERAPEUTICS - RiverVest
Aug 3, 2023 Good Therapeutics, founded in 2016 by molecular biologist John Mulligan, Ph.D., was acquired by Roche in 2022 for $250 million upfront plus potential milestone payments. Even better, Mulligan and company retained โฆSee details»
Roche to acquire Good Therapeutics' lead drug โฆ
Sep 7, 2022 Good Therapeutics previously raised $600,000 in Seed funding, $22 million in a Series A round in 2020 and $10 million in a recent Series B round. Roche Venture Fund is an investor.See details»
Seattle biotech startup Good Therapeutics raises $11M โฆ
Feb 19, 2019 Good Therapeutics, a new Seattle biotech startup that aims to develop protein drugs that act only when needed, raised $11 million in an equity round, according to a new SEC filing.. The secretive ...See details»
Roche to Acquire Good Therapeutics for $250 Million - PharmTech
Sep 8, 2022 Good Therapeutics, a privately held biopharmaceutical company, announced on Sept. 7, 2022 that it has entered into a definitive merger to be acquired by Roche for $250 โฆSee details»
Good Therapeutics Being Acquired by Roche for $250M
Sep 13, 2022 The whole Good Therapeutics team will be retained by Bonum. โWith our proven track record in cancer immunotherapy, we are well-positioned to leverage our deep discovery, โฆSee details»
Roche to pay $250M for Good Therapeutics and its targeted drug ...
Sep 7, 2022 Roche will pay $250 million in cash to take over privately held Good Therapeutics and gain access to a program designed to produce more selective cancer drugs. The deal, โฆSee details»
Founder & CEO John Mulligan Shares Good Therapeutics
Jan 31, 2022 We founded Good Therapeutics to create a new kind of context-dependent drug that is active only when and where it is needed. When we started, many natural proteins were โฆSee details»
Good Therapeutics raises $11M to develop โcontext ... - GeekWire
May 21, 2020 Seattle biotech startup Good Therapeutics raised another $11 million to create "context dependent" protein drugs that act only when needed. The 4-year-old. Toggle search โฆSee details»
Roche pays $250 million to acquire Good Therapeutics - STAT
Sep 7, 2022 Good Therapeutics, a private company that raised just $30 million in venture financing since its 2016 foundation, said it had signed a deal to sell itself to Roche for $250 โฆSee details»
Bonum Therapeutics Announces a $93M Series A Financing to โฆ
Nov 15, 2022 Bonum is a spinout of Good Therapeutics, which Roche acquired in August 2022 for $250 million upfront plus potential milestone payments. The investor syndicate that โฆSee details»
Good Therapeutics Strengthens Senior Management Team with
Dec 9, 2021 SEATTLE--(BUSINESS WIRE)--Good Therapeutics, Inc. today announced appointments of Diane Hollenbaugh, PhD and Neela Patel, PhD to the companyโs senior โฆSee details»
Bonum Therapeutics Raises $93M with Allosterically Regulated โฆ
Nov 15, 2022 Bonum spun off from Good Therapeutics, which was acquired by Roche in August 2022 for a $250-million upfront payment with future milestone payments. The investor โฆSee details»